• Corpus ID: 10233356

Alanosine (UCSD).

@article{Yu2001Alanosine,
  title={Alanosine (UCSD).},
  author={J Yu},
  journal={Current opinion in investigational drugs},
  year={2001},
  volume={2 11},
  pages={
          1623-30
        }
}
  • J. Yu
  • Published 2001
  • Biology
  • Current opinion in investigational drugs
Researchers at the University of California at San Diego (UCSD) are developing alanosine as a potential treatment for cancer [227466], [408222]. The compound was originally under development in collaboration with Triangle, which initiated its development in 1996 [227466], but later discontinued development of the compound [406677]. As of May 2001, UCSD's ongoing clinical trials of alanosine included phase II trials for non-small cell lung cancer (NSCLC) and phase I trials for acute lymphoid… 
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer
TLDR
At this dose and schedule, L-alanosine was ineffective in patients with advanced MTAP-deficient tumors, and there were no objective responses.
Circadian pharmacology of l-alanosine (SDX-102) in mice
TLDR
The therapeutic index of SDx-102 was improved by the delivery of SDX-102 in the mid to late activity span, and the concept of chronomodulated infusion ofSDX- 102 in cancer patients is supported.
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
TLDR
Homozygous deletion of CDKN2A is seen in the majority of pleural mesotheliomas, and MTAP is codeleted in most of these cases, which makes it an ideal candidate for trials of targeted therapy using inhibitors of de novo AMP synthesis.
CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono‐ and bi‐allelic 9p21 deletions in childhood acute lymphoblastic leukemia
TLDR
It is shown that, if several controls and adjustments are performed, real‐time PCR can provide a reliable test for mono‐ and bi‐allelic deletions in ALL and proposes a strategy that overcomes the major caveats of such a dosage in tumor samples: aneuploidy and contamination by normal cells.
Synthesis of Enantiomerically Pure N-Boc-Protected 1,2,3-Triaminopropylphosphonates and 1,2-Diamino-3-Hydroxypropylphosphonates
All possible isomers of 1,2,3-tri(N-tert-butoxycarbonylamino)propylphosphonate 6 were synthesized from the respective diethyl [N-(1-phenylethyl)]-1-benzylamino-2,3-epiiminopropylphosphonates 5 via